2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 02:07, 23 October 2023
, 23 October 2023→Clinical Trials
No edit summary |
|||
| Line 143: | Line 143: | ||
!Outcome | !Outcome | ||
|- | |- | ||
|Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men {{#pmid:31685720|pmid31685720}} | |Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men {{#pmid:31685720|pmid31685720|url=https://www.jstage.jst.go.jp/article/endocrj/67/2/67_EJ19-0313/_html/-char/en}} | ||
| | | | ||
* singe admission of up to 500 mg | * singe admission of up to 500 mg | ||